Open AccessBilateral adrenal haemorrhage secondary to rivaroxaban in a patient with antiphospholipid syndrome
Author(s) -
Marilyn Arosemena,
Andrés Rodríguez,
Hasini Ediriweera
Publication year - 2020
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2020-234947
Subject(s) - medicine , rivaroxaban , antiphospholipid syndrome , adrenal insufficiency , adrenal disorder , pulmonary embolism , intensive care unit , warfarin , regimen , thrombosis , surgery , intensive care medicine , pediatrics , atrial fibrillation , insulin resistance , glucose homeostasis , insulin
A 46-year-old man with antiphospholipid syndrome (APS) and previous pulmonary embolism on anticoagulation with rivaroxaban was brought in to the hospital after a syncopal episode. He was found to be hypotensive and tachycardic and later admitted to the intensive care unit. Clinical presentation and laboratory findings were consistent with adrenal insufficiency. MRI revealed bilateral adrenal haemorrhage and he received appropriate steroid replacement therapy. Symptoms slowly subsided and anticoagulation regimen was changed to warfarin. Adrenal haemorrhage was likely caused by APS and rivaroxaban, which brings into question whether novel oral anticoagulants are safe in this patient population.